Recent Company News

• 05:24 AM ET Jun 11, 2025
  

  StreetAccount Summary: EU stocks reaching new 52-week highs/lows (74 total)

• 07:08 AM ET Jun 02, 2025
  

  Novonesis completes acquisition of dsm-firmenichs's share of the Feed Enzyme Alliance (DKK 467.80, +6.00)

• 01:39 AM ET May 29, 2025
  

  Novonesis initiated overweight at Morgan Stanley (DKK 461.80, 0.00)

• 08:08 AM ET May 27, 2025
  

  Savara receives Refusal to File (RTF) letter from FDA for BLA for MOLBREEVI to treat patients with autoimmune PAP ($2.84, 0.00)

• 04:50 PM ET May 18, 2025
  

  Savara reports new data presented from the Phase 3 IMPALA-2 clinical trial of molgramostim at the ATS International Conference 2025 ($3.07, 0.00)

• 04:04 AM ET May 08, 2025
  

  StreetAccount Summary - Trading higher/lower: EU mid-morning

• 02:59 AM ET May 08, 2025
  

  StreetAccount Summary - European pre-market trading update

• 02:36 AM ET May 08, 2025
  

  StreetAccount Metrics Recap - Novonesis Q1 Earnings (DKK 425.70, 0.00)

• 02:03 AM ET May 08, 2025
  

  Novonesis reports Q1 EPS €0.40 vs FactSet €0.40 [2 est, €0.39-0.40] (DKK 425.70, 0.00)

• 06:31 AM ET May 07, 2025
  

  StreetAccount Consensus Metrics Preview - Novonesis Q1 Earnings (DKK 429.30, +2.00)